Yutaka Sasaki - Concepedia

Author

Yutaka Sasaki

Also Known As

Sasaki, Y., Y SASAKI, Y Sasaki, Y. Sasaki, YUTAKA SASAKI, Yutaka SASAKI, Yutaka Sasaki, Yutaka Sasaki (286423), Yutaka Sasaki‡

410

Publications

13.5K

Citations

H-Index

238

Concepts

All Affiliations

The University of Osaka Kumamoto University Kansai Medical University Kyoto University

About

Yutaka Sasaki is an author at The University of Osaka specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	99	9K
2	Health Sciences	19	31	5.8K
3	Engineering	6	6	163
4	Natural Sciences	5	5	180
5	Social Sciences	3	3	87

Yutaka Sasaki

179

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential Jörgen Adolfsson, Robert Månsson, Natalija Buza-Vidas, Cell Developmental BiologyMedicineHematologyMyeloid NeoplasiaBlood Cell	2005	1.2K
Upregulation of Flt3 Expression within the Bone Marrow Lin−Sca1+c-kit+ Stem Cell Compartment Is Accompanied by Loss of Self-Renewal Capacity Jörgen Adolfsson, Ole Johan Borge, David Bryder, Immunity Developmental BiologySelf-renewal CapacityMedicineStem Cell EngineeringHematology	2001	691
Impaired Allostimulatory Capacity of Peripheral Blood Dendritic Cells Recovered from Hepatitis C Virus-Infected Individuals Tatsuya Kanto, Norio Hayashi, Tetsuo Takehara, The Journal of Immunology	1999	358
Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma Yoshiki Ito, Yutaka Sasaki, Masayoshi Horimoto, Hepatology Signal TransductionHepatologyTumor MicroenvironmentHuman Hepatocellular CarcinomaHuman Hcc	1998	337
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, The Lancet. Gastroenterology & hepatology HepatologyMedicineClinical TrialsLiver CancerAdvanced Hepatocellular Carcinoma	2018	303
Critical Role of MHC Class I-Related Chain A and B Expression on IFN-α-Stimulated Dendritic Cells in NK Cell Activation: Impairment in Chronic Hepatitis C Virus Infection Masahisa Jinushi, Tetsuo Takehara, Tatsuya Kanto, The Journal of Immunology Adaptive Immune SystemImmunologyImmune RegulationImmunologic MechanismCd4 T Cell Responses	2003	257
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254
Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid Masahisa Jinushi, Tetsuo Takehara, Tomohide Tatsumi, International Journal of Cancer	2003	243
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update Ryosuke Tateishi, Koji Uchino, Naoto Fujiwara, Journal of Gastroenterology	2018	235

Page 1